Cell-Based Assay for Simultaneous Antibody Binding and Function
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for developing antibody-based therapeutic reagents face challenges in early-stage assessment of antibody binding and functionality, requiring separate assays for target specificity, affinity, and physiological relevance, which can be time-consuming and inefficient.
Innovation Solution
A novel in vitro assay that combines the assessment of binding and functionality of antibodies or ligands by using cells expressing target antigens labeled with energy donor compounds and reporter genes, allowing for simultaneous measurement of energy transfer and reporter gene expression to determine binding and functional activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If separate assays are used to assess binding and functionality of antibodies, then measurement precision for each parameter is improved, but productivity is reduced due to time-consuming multiple testing steps
Solution Approach 1:
The patent combines binding assessment (via FRET signal between donor on cell surface and acceptor on antibody) and functionality assessment (via reporter gene expression) into a single integrated assay performed in the same well. This merging of previously separate assays enables simultaneous measurement of both binding and functional activity, thereby improving productivity without sacrificing measurement precision through the use of dual-readout detection systems.
Solution Approach 2:
The assay system is designed with multi-functionality to perform multiple assessment tasks simultaneously: (1) binding detection through FRET, (2) functional activity detection through reporter gene expression, and (3) correlation analysis between binding and function. This universal assay platform eliminates the need for multiple separate tests while maintaining comprehensive evaluation capabilities.
2Reliability
If multiple separate assays are conducted for antibody characterization, then reliability of individual measurements is improved, but loss of time increases due to sequential testing requirements
Solution Approach 1:
The patent implements continuous useful action by performing binding and functionality assessments in an uninterrupted single-step assay. The FRET-based binding detection and reporter gene-based functional detection occur simultaneously in the same experimental condition, eliminating the need to stop, reset, or change conditions between tests. This continuous assessment approach maintains measurement reliability while dramatically reducing the time required for complete antibody characterization.
3Device complexity
If conventional separate binding and functionality assays are used, then device complexity is reduced with simpler individual tests, but measurement precision for correlated parameters deteriorates due to lack of simultaneous measurement
Solution Approach 1:
The patent adds another dimension to the assay by implementing dual-readout detection: optical FRET signal detection for binding assessment and luminescent/fluorescent reporter gene detection for functionality assessment. This multi-dimensional detection approach allows simultaneous measurement of multiple parameters with high precision while managing system complexity through modular detector design that can process multiple signal types independently.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables early identification of optimal antibody candidates by concurrently evaluating binding and functional activity, streamlining the drug development process and reducing the need for multiple assays, thus accelerating the identification of effective therapeutic molecules.
Implementation Method 1
measuring the binding to the target antigen by determining the energy transfer, wherein the energy acceptor compound is covalently or noncovalently conjugated either to the antibody to be tested or to a secondary antibody binding to the first antibody
Implementation Method 2
the FRET is time resolved FRET
Data Source
AI summary
The present invention relates to a new cell based assay for combined determination of antibody or ligand binding and function in the same vial.


